Abstract:Abstract Chronic hepatitis B virus (HBV) infection is strongly associated with the initiation and development of hepatocellular carcinoma (HCC). However, the genetic alterations and pathogenesis mechanisms remain significantly unexplored, especially for HBV-induced metabolic reprogramming. Analysis of integration breakpoints in HBV-positive HCC samples revealed the preferential clustering pattern within the 3′-end of X gene in the HBV genome, leading to the production of C-terminal truncated X protein (Ct-HBx). In this study, we not only characterized the oncogenic role of two Ct-HBx (HBx-120 and HBx-134) via in vitro and in vivo functional assays but also deciphered their underlying molecular mechanisms. Gene expression profiling by transcriptome sequencing identified potential targets of Ct-HBx and novel malignant hallmarks such as glycolysis, cell cycle, and m-TORC1 signaling in Ct-HBx-expressing cells. TXNIP, a well-established regulator of glucose metabolism, was shown to be downregulated by Ct-HBx and play a pivotal role in Ct-HBx-mediated HCC progression. Suppression of TXNIP is frequently observed in HCC patients with Ct-HBx expression and significantly ( P = 0.015) correlated to a poorer prognosis. Re-introduction of TXNIP attenuated the metabolic reprogramming induced by the Ct-HBx and inhibited the tumor growth in the mice model. Further study suggested that Ct-HBx could downregulate TXNIP via a transcriptional repressor nuclear factor of activated T cells 2 (NFACT2). Collectively, our findings indicate that TXNIP plays a critical role in Ct-HBx-mediated hepatocarcinogenesis, serving as a novel therapeutic strategy in HCC treatment.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how hepatitis B virus (HBV) infection triggers the occurrence and development of hepatocellular carcinoma (HCC) through the C - terminal truncated HBx protein (Ct - HBx). Specifically, the researchers focused on the role of Ct - HBx in down - regulating the expression of thioredoxin - interacting protein (TXNIP) and reprogramming glucose metabolism, so as to reveal the mechanism of HBV - induced liver cancer. The paper mentioned that chronic HBV infection is closely related to the initiation and development of HCC, but there are still many unsolved mysteries regarding the genetic alterations and pathogenesis caused by HBV, especially in terms of HBV - induced metabolic reprogramming. Through the analysis of integration breakpoints in HBV - positive HCC samples, the researchers found that these breakpoints tend to cluster within the 3' - end X gene of the HBV genome, resulting in the production of Ct - HBx. This study not only characterized the oncogenic effects of two Ct - HBx (HBx - 120 and HBx - 134) through in vitro and in vivo functional tests, but also analyzed their underlying molecular mechanisms. Through transcriptome sequencing analysis, the potential targets of Ct - HBx and new malignant markers, such as glycolysis, cell cycle and m - TORC1 signaling pathways, were identified. The study found that TXNIP, as a known glucose - metabolism regulator, is down - regulated in Ct - HBx - expressing cells and plays a crucial role in Ct - HBx - mediated HCC progression. The inhibition of TXNIP was frequently observed in HCC patients expressing Ct - HBx and was significantly (P = 0.015) associated with a poorer prognosis. Re - introducing TXNIP can attenuate the metabolic reprogramming caused by Ct - HBx and inhibit tumor growth in mouse models. Further research indicates that Ct - HBx may down - regulate TXNIP through the transcriptional repressor nuclear factor of activated T - cells 2 (NFATC2). Overall, these findings suggest that TXNIP plays an important role in Ct - HBx - mediated liver cancerogenesis and may become a new strategy for HCC treatment.

C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism